Werke:
- Identification and validation of a novel biologics target in triple negative breast cancer
- Molecular differences between younger versus older ER-positive and HER2-negative breast cancers
- Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy
- Control of dataset bias in combined affymetrix cohorts of triple negative breast cancer